

Review of: "The potential of GLP-1 RAs in treating Tobacco use dependence and Obesity"

Kazunori Sango

Potential competing interests: No potential competing interests to declare.

Through the search of PubMed, the authors indicated the potential efficacy of GLP-1RAs against smoking and obesity. The manuscript is very interesting and informative, but a few issues need to be addressed.

Major concerns:

1. Although the form of manuscript is original research, it is a mini review because the results are completely based on the previous studies.
2. It is slightly difficult to understand the possible action mechanisms of how GLP-1 and GLP-1RA suppress the appetite and nicotine intake. For readers' convenience, schematic representation of GLP-1 signaling and actions in the brain would be desirable.
3. It would be desirable to depict practical utilization of GLP-1RA toward diabetic smokers.

Minor points:

1. Page 2, Line 5: what does [SG] mean?
2. Page 2, Line13: [GLP-1 agonists] should be [GLP-1RAs].
3. Page 2, Line 11 from the bottom: what is [activity deficits]? More precise description is needed.
4. Page 2, Line 10 from the bottom: [various] mechanisms should be described in more detail.
5. Page 2, Line 5 from the bottom: what does GLP-1 neurons mean? Are these GLP-1 or GLP-1R expressing neurons?
6. Page 2, Line 3 from the bottom: [Both of which] should be [Both drugs].
7. Page 3, Line18: body weight (from kg to kg?)
8. Page 4, Line 2: please do not use [pounds] but [kg].